Skip to main content
Premium Trial:

Request an Annual Quote

Dmitry Samarsky, Kreatech

Premium

People in the News

Dmitry Samarsky has recently been named director of technology development at Dharmacon.

Previously, Samarsky was with Invitrogen, where he formulated partnership models and helped develop platform solutions for the drug discovery process, according to Dhamacon. Before that, he was with Sequitur, which was acquired by Invitrogen in late 2003 (see ).

Samarsky holds a PhD from the University of Massachusetts, Amherst.

 

Products & Services

Kreatech said this week that it has released the small RNA labeling kit.

According to the company, the kit uses ULS labeling technology to directly label any and all sizes of naturally occurring nucleic acids, including microRNAs and siRNAs, without the need of enzymes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more